Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir
Volume: 116, Issue: 6, Pages: 1264 - 1273
Published: Feb 2, 2021
Abstract
INTRODUCTION: Entecavir (ETV) and tenofovir alafenamide (TAF) are both first-line hepatitis B virus (HBV) therapies, but ETV-to-TAF switch outcome data are limited. We aimed to assess outcomes up to 96 weeks after ETV-to-TAF switch. METHODS: ETV-treated (≥12 months) chronic hepatitis B patients switched to TAF in routine practice at 15 centers (United States, Korea, Japan, and Taiwan) were included. Primary outcome was complete viral suppression...
Paper Details
Title
Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir
Published Date
Feb 2, 2021
Volume
116
Issue
6
Pages
1264 - 1273
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History